Annals of Surgical Oncology

, Volume 18, Issue 6, pp 1624–1629

Medium-Sized (3.1–5.0 cm) Hepatocellular Carcinoma: Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Radiofrequency Ablation Alone

Authors

    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
  • Hyung Jin Won
    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
  • Yong Moon Shin
    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
  • Sung Hee Kim
    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
  • Hyun-Ki Yoon
    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
  • Kyu-Bo Sung
    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
  • Pyo Nyun Kim
    • Department of RadiologyAsan Medical Center, University of Ulsan College of Medicine
    • Research Institute of RadiologyAsan Medical Center, University of Ulsan College of Medicine
Hepatobiliary Tumors

DOI: 10.1245/s10434-011-1673-8

Cite this article as:
Kim, J.H., Won, H.J., Shin, Y.M. et al. Ann Surg Oncol (2011) 18: 1624. doi:10.1245/s10434-011-1673-8

Abstract

Purpose

This study was designed to retrospectively compare the effectiveness of combined transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with that of RFA alone in patients with medium-sized (3.1–5.0 cm) hepatocellular carcinoma (HCC).

Methods

From March 2000 to April 2010, 57 patients, each with a single medium-sized HCC, were treated with combined TACE and RFA, and 66 were treated with RFA alone.

Results

During follow-up (mean, 42.5 ± 33.2 months; range, 2.6–126.2 months), local tumor progression was observed in 40% of treated lesions in the combined treatment group and in 70% in the RFA-alone group. The 1-, 3-, 5-, and 7-year local tumor progression rates were significantly lower in the TACE + RFA group (9%, 40%, 55%, and 66%, respectively) than in the RFA-alone group (45%, 76%, 86%, and 89%, respectively; P < 0.001). Multivariate analysis showed that treatment allocation (odds ratio [OR], 1.78; P = 0.016) and Child-Pugh class (OR, 1.96; P = 0.008) were significant independent factors associated with patient survival. The rates of major complications were 0% for the combined treatment group and 3% for the RFA-alone group.

Conclusions

The combination of TACE and RFA is safe and provides better local tumor control than RFA alone for the treatment of patients with medium-sized HCC. Our multivariate analysis showed that RFA-alone treatment and Child-Pugh class B were poor independent factors for determining the patient survival period.

Copyright information

© Society of Surgical Oncology 2011